KDM3B and ovarian cancer: Taken together, we provide several lines of evidence that pharmacological targeting of the histone demethylases JMJD1B/C by the inhibitor methylstat results in an efficient PARPi sensitization in ovarian cancer cells, independently of the inherent PARPi-resistance status or the BRCA1 mutational background.